[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"muscle-pain\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:muscle-pain":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,79],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100600211","phase-2-jaw-muscle-pain-post-wisdom-molar-surgery-100600211",false,"NCT07094542","Jaw Muscle Pain Post Wisdom Molar Surgery","Temporo-masseteric Nerve Block in Post-wisdom Tooth Extraction Pain- a Randomized Study","Inclusion Criteria:\n\nAll patients recommended extraction\u002Fs of at least 1 lower wisdom (third) molar that is partially\u002Ffully 'impacted' under intravenous sedation, are eligible to participate in this study so long as they\n\n* are 18 years or older,\n* are healthy,\n* have no cognitive\u002Fintellectual disability,\n* have no past\u002Frecent pain or reduced range of motion in their jaw joint\u002F muscle complex, no trauma or surgery in their jaw region.\n* have an electronic device such as a smart phone or a tablet\u002F computer with internet connection.\n* are willing to participate in the study and not be excluded by the following criteria below.\n\nExclusion Criteria:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Compromised ability to guard their self-interest, for e.g., prisoners, children, pregnant women, patients with intellectual\u002Fcognitive disability are not enrolled in the study.\n* Those patients who present with infection\u002Finflammation involving the third molars slated for extractions, on the day of their procedure, may not take part in the study.\n* Those who have had opioid pain medication\u002Fs in the past 3 months to address short term or long-standing pain, or those who are on long term prescription of anti-inflammatory pain medication, are unable to participate.\n* Those with long standing painful limitation of movement of the jaw joint or muscles.\n* Those patients who are allergic to\u002Funable to tolerate either the dental local anesthetic or its components, opioids, acetaminophen or ibuprofen also may not take part in the study","ALL","18 Years",{"count":19,"type":20},80,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The proposed design is a triple-blind, placebo-controlled randomized prospective phase II trial to assess the feasibility of employing the Temporo-masseteric Nerve Block (TMNB) injection to decrease jaw muscle pain, overall pain, improve mouth opening and minimize pain medication consumption. 80 participants undergoing lower third molar removal under sedation will be enrolled. Those who develop significant jaw muscle pain on the following day will be randomized to receive either the TMNB injection or a placebo. Daily ecological momentary assessments (EMAs) will be collected reflecting elements of patient experience for all participants. On Day 8, participants return for an end-of-study evaluation and return their unused pain medications. Up to 40 participants who are randomized to receive TMNB\u002Fplacebo will be recruited to participate in a qualitative interview regarding their experience.",[26,27,28],"Post Operative Pain","Impacted Third Molar Tooth","Muscle Pain",[30,31],"Temporo-masseteric Nerve Block","Jaw muscle pain","NOT_YET_RECRUITING","2026-06-17",{"date":35,"type":36},"2026-06-18","ACTUAL",{"date":38,"type":20},"2026-09",{"date":40,"type":20},"2030-05",{"name":42,"class":43},"Rutgers, The State University of New Jersey","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":16,"minAge":17,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100593263","effects-of-tpr-and-z-techniques-on-pain-and-drug-leakage-in-intramuscular-injections-100593263","NCT07004166","Effects of TPR and Z Techniques on Pain and Drug Leakage in Intramuscular Injections","Effects of TPR Technique and Z Technique on Pain and Drug Leakage in Intramuscular Injections","TPR_Z_PainLeak","Inclusion Criteria:\n\n* Aged 16-40\n* Prescribed diclofenac sodium\n* No communication impairments\n* Healthy ventrogluteal muscles without sensory issues\n\nExclusion Criteria:\n\n* Wounds, redness, bruising, tenderness, or stiffness at the injection site\n* Injection in the past 2 weeks\n* Neuropathy or other medical conditions\n* BMI below 15 or above 35",true,"40 Years",{"count":56,"type":20},76,[58],"NA","This randomized, triple-blind clinical trial compares the effectiveness of Z-track and TPR (traction-pressure-release) techniques in reducing pain and medication leakage during ventrogluteal intramuscular injections. Pain is measured using VAS, and leakage is assessed with a millimeter scale. The study aims to identify a more efficient, less painful injection method.",[28,61],"Injection Site Pain",[63,64,65,66,67],"Intramuscular Injection","Drug Leakage l","Pain","Z-Track","TPR Techniques","RECRUITING","2025-06-03",{"date":71,"type":36},"2025-06-04",{"date":73,"type":20},"2025-06-15",{"date":75,"type":20},"2025-08-25",{"name":77,"class":43},"Cumhuriyet University",2,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":53,"sex":16,"minAge":17,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":21,"phases":89,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":4},"100555309","phase-1-an-bioequivalence-study-of-loxoprofen-sodium-patches-in-healthy-volunteers-100555309","NCT06510413","An Bioequivalence Study of Loxoprofen Sodium Patches in Healthy Volunteers","An Bioequivalence Study of Loxoprofen Sodium Patches in Chinese Healthy Volunteers","Inclusion Criteria:\n\n* Male weight ≥50 kg, female weight ≥45 kg, body mass index (BMI) between 19.0 and 28.0 kg\u002Fm2, inclusive .\n* Informed consent: signed written informed consent before inclusion in the study.\n* The subjects are well communicated and are able to comply with the requirements of the study\n\nExclusion Criteria:\n\n* Participated in other drug intervention studies within 90 days\n* Allergic to this product and excipients, or have a history of food, drug allergy or other allergic diseases (asthma, urticaria, eczema dermatitis, etc.)\n* Aspirin asthma\n* Any visible skin disorder or abnormal skin pigmentation which, in the opinion of the investigator, would interfere with the outcome of the trial.\n* A history of cardiovascular system, respiratory system, digestive system, urinary system, endocrine system, immune system, nervous\u002Fpsychiatric system, blood and lymphatic system, and skeletal musculoskeletal system that investigator have determined to be abnormal and clinically significant\n* Postural hypotension, needle fainting or blood fainting history or venipuncture intolerance\n* Any drug that inhibits or induces liver metabolism has been used in the 30 days prior to screening. Inducers: barbiturates, carbamazepine, phenytoin sodium, glucocorticoids, omeprazole; Inhibitors: SSRI antidepressants, cimetidine, Diltiazem, nitroimidazoles, sedatives and hypnotics, verapamil, fluoroquinolones, antihistamines\n* Blood donation or significant blood loss (\\>400 mL, except for female menstrual period) in the 3 months prior to screening, blood transfusion or use of blood products, or have a blood donation plan during\u002Fwithin 3 months after the study\n* Smoked more than 5 cigarettes per day in the 3 months prior to screening, or unwilling to prohibit the use of any tobacco products during the trial period\n* History of alcohol abuse within 6 months\n* Subjects who consumed excessive amounts of tea, coffee or caffeinated beverages within 3 months, or who did not agree to the prohibition of tea, coffee or caffeinated beverages in the study\n* Subjects who have special requirements for diet and cannot comply with a unified diet\n* History of drug abuse within 1 year\n* Subjects who have unprotected sex in 2 weeks, or planned to have a child during the study period, planned to donate sperm and eggs, or are unwilling to use one or more non-drug contraceptive methods during the study, or are unwilling to use contraception within 3 months after the study\n* Pregnant or nursing women\n* Positive skin scratch test positive\n* Clinically significant vital signs laboratory, physical examination, or 12-lead electrocardiogram abnormalities as judged by the investigator\n* Other situations that the investigator determines are not suitable for participating in this clinical trial","65 Years",{"count":88,"type":20},40,[90],"PHASE1","This study was a single-center, randomized, open-label, two-agent, two-cycle, double-cross bioequivalence trial.",[93,28,94],"Osteoarthritis","Swelling Muscle","2024-07-15",{"date":97,"type":36},"2024-07-19",{"date":99,"type":20},"2024-07",{"date":101,"type":20},"2024-08",{"name":103,"class":104},"Frontier Biotechnologies Inc.","INDUSTRY"]